ENTEROEntero Healthcare Solutions Limited
Healthcare · Medical Distribution · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ENTERO — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 38.2% YoY
- • Profit growth: 37.3% YoY
- • Debt/Equity: 0.39
- • RSI: 70
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 38.2% YoY
- • Profit growth: 37.3% YoY
- • Debt/Equity: 0.39
- • RSI: 70
Bear case
- • ROE: 6.8%
- • ROCE: 9.4%
- • MACD: bearish
- • Volume: 0.2x 20-day average
Key risks
- • ROE: 6.8%
- • ROCE: 9.4%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹70.21). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.